NASDAQ:HCM 延时15分钟

成交量

Dan Eldar: Dan Eldar currently works at HUTCHMED (China) Ltd., as Chairman from 2024, Hutchison Water Israel E.P.C Ltd., as Director, S.D. Sight Diagnostics Ltd., as Director from 2019, Hutchison Biofilm Medical Solutions Ltd., as Director, DayTwo Ltd., as Director from 2019, and Longliv Ventures LP, as Managing Director from 2018. Dr. Eldar also formerly worked at Max It Finance Ltd., as Independent Non-Executive Director, Hutchison Kinrot, as Director, Leumi Card Ltd., as Independent Non-Executive Director, Leumi Card Ltd., as Member of the Board of Directors from 2013 to 2016, Partner Communications Co. Ltd., as Vice President-Investor Relations, and AceAge, Inc., as Board Member from 2020 to 2022. Dr. Eldar received his graduate degree and doctorate degree from Harvard University and undergraduate degree and graduate degree from The Hebrew University of Jerusalem.

Edith Shih: Edith Shih currently works at The Hong Kong University of Science & Technology, as Vice Chairman-Council, Accounting & Financial Reporting Council, as Chairman-Process Review Panel, Maritime Transport Services Ltd., as Director, and various other companies. Ms. Shih also formerly worked at China Oceanwide Holdings Ltd., as Secretary & Executive Director from 2012 to 2014, VC Capital Ltd., as Director from 1989 to 1991, H3G SpA, as Director, and various other companies. Ms. Shih received her graduate degree from The Trustees of Columbia University in The City of New York and undergraduate degree and graduate degree from the University of the Philippines.; 旧服务已下线，请迁移至 http://api.fanyi.baidu.com

Chig Fung Cheng: Chig Fung Cheng currently works at HUTCHMED (China) Ltd., as CEO, Chief Financial Officer & Executive Director from 2025, Hutchison MediPharma Ltd., as Director, Sen Medicine Co. Ltd., as Director, Hutchison Medipharma (Hong Kong) Ltd., as Director, Hutchison Medipharma (Suzhou) Ltd., as Director, The Institute of Chartered Accountants in Australia, as Member, and Chartered Accountants Australia & New Zealand, as Member. Mr. Cheng also formerly worked at Hutchison Healthcare Ltd., as Director, Bristol-Myers Squibb (China) Investment Co. Ltd., as Director from 2006 to 2008, Sino-American Shanghai Squibb Pharmaceuticals Ltd., as Director, PricewaterhouseCoopers (Australia), as Auditor, Bristol-Myers Squibb (China) Pharmaceuticals Co. Ltd., as Vice President-Finance, Nestl (China) Ltd., as Controller, and KPMG Beijing, as Auditor. Mr. Cheng received his undergraduate degree from the University of Adelaide.; 旧服务已下线，请迁移至 http://api.fanyi.baidu.com

Wei Guo Su: Wei Guo Su currently works at HUTCHMED (China) Ltd., as Executive Director & Chief Scientific Officer from 2025, ImageneBio, Inc., as Independent Director from 2025, and Hutchison MediPharma Ltd., as Chief Scientific Officer & Executive VP from 2012. Dr. Su also formerly worked at Pfizer Inc., as Director-Medicinal Chemistry Department. Dr. Su received his doctorate degree from Harvard University and undergraduate degree from Fudan University.

Dan Eldar: Dan Eldar currently works at HUTCHMED (China) Ltd., as Chairman from 2024, Hutchison Water Israel E.P.C Ltd., as Director, S.D. Sight Diagnostics Ltd., as Director from 2019, Hutchison Biofilm Medical Solutions Ltd., as Director, DayTwo Ltd., as Director from 2019, and Longliv Ventures LP, as Managing Director from 2018. Dr. Eldar also formerly worked at Max It Finance Ltd., as Independent Non-Executive Director, Hutchison Kinrot, as Director, Leumi Card Ltd., as Independent Non-Executive Director, Leumi Card Ltd., as Member of the Board of Directors from 2013 to 2016, Partner Communications Co. Ltd., as Vice President-Investor Relations, and AceAge, Inc., as Board Member from 2020 to 2022. Dr. Eldar received his graduate degree and doctorate degree from Harvard University and undergraduate degree and graduate degree from The Hebrew University of Jerusalem.

Shu Kam Mok: Shu Kam Mok was the founder of Sanomics Ltd. (2015, Chairman). Dr. Mok is also the founder of Chinese Thoracic Oncology Group, Asia Thoracic Oncology Research Group, Aurora Tele-Oncology Ltd. Current jobs include Independent Non-Executive Director at AstraZeneca PLC (2019), Lead Independent Non-Executive Director at HUTCHMED (China) Ltd. (2017), Non-Executive Independent Director at Lunit Usa, Inc., Director at Insighta Ltd., and Secretary at Chinese Society of Clinical Oncology. Former jobs include Chairman-Clinical Oncology Department at The Chinese University of Hong Kong, Chairman at ACT Genomics Co. Ltd., Director at American Society of Clinical Oncology, Inc., and Treasurer at International Association for the Study of Lung Cancer. Education includes undergraduate and doctorate degrees from the University of Alberta.

Ling Yang: Ling Yang currently works at Hangzhou Adicon Clinical Laboratories, Inc., as Chairman from 2018, ADICON Holdings Ltd., as Non-Executive Chairman from 2018, HUTCHMED (China) Ltd., as Non-Executive Director from 2023, Ambio Pharmaceuticals, as Non-Executive Director from 2021, Ambio, Inc., as Director, Carlyle Asia Investment Advisors Ltd., as Managing Director from 2011, and The Phi Beta Kappa Society, as Member. Ms. Yang also formerly worked at Shenzhen Salubris Pharmaceuticals Co., Ltd., as Director, Ambio Holdings, Inc., as Director, The Carlyle Group Inc., as Vice President & Managing Director, KKR Asia Ltd., as Principal from 2008 to 2011, The Carlyle Group Inc., as Associate from 2005 to 2006, and Kohlberg Kravis Roberts & Co.(Beijing), as Principal from 2008 to 2011. Ms. Yang received her undergraduate degree in 2002 from Smith College and Masters Business Admin degree in 2008 from Harvard Business School.

Renu Bhatia: Renu Bhatia currently works at HUTCHMED (China) Ltd., as Independent Non-Executive Director from 2024 and Opharmic Technology (HK) Ltd., as Director. Dr. Bhatia received her graduate degree from The University of Hong Kong, doctorate degree from the University of London, and Masters Business Admin degree from Yale University.

Chao Hong Hu: Dr. Chao Hong Hu is an Independent Non-Executive Director at HUTCHMED (China) Ltd. He is on the Board of Directors at HUTCHMED (China) Ltd. Dr. Hu was previously employed as a Co-Chief Executive Officer & Executive Director by Lepu Biopharma Co., Ltd., a Chairman & General Manager by Shanghai Miracogen, Inc., a Director-Bioassay Development & Process Analytics by Seattle Genetics, Inc., a Head-Molecular Biology & Clinical Immunology by GlaxoSmithKline Plc, and a Director-Molecular Biology & Clinical Immunology by ID Biomedical Corp. He received his undergraduate degree from Wuhan University and a doctorate degree from Chinese Academy of Sciences.

Shao Weng Tan: Shao Weng Tan currently works at HUTCHMED (China) Ltd., as Independent Non-Executive Director from 2025, American Society of Clinical Oncology, Inc., as Member, The Royal College of Physicians, as Member, European Society for Medical Oncology, as Member, International Association for the Study of Lung Cancer, as Member, Singapore Society of Oncology, as Member, and The American Association of Cancer Research, as Member. Dr. Tan received his doctorate degree from National University of Singapore, undergraduate degree from University College London, undergraduate degree from St Bartholomew's Hospital Medical College, and undergraduate degree from Queen Mary University of London.

和黄药业